ImpediMed Q4 FY26 slides: mixed results despite improved cash position
ImpediMed Limited (ASX:IPD) presented its fourth-quarter fiscal 2026 results on July 28, 2026, showing improved cash collections and unit sales but acknowledging execution challenges that have weighed on the stock. The medical device company, which sells its SOZO digital health platform for fluid and body composition monitoring, reported progress across several operational metrics while trading near the bottom of its 52-week range at $0.004 per share, down 92% over the past year.
Reported by 2 outlets — Investing.com · Company News. See all sources ↓
ImpediMed Limited (ASX:IPD) presented its fourth-quarter fiscal 2026 results on July 28, 2026, showing improved cash collections and unit sales but acknowledging execution challenges that have weighed on the stock. The medical device company, which sells its SOZO digital health platform for fluid and body composition monitoring, reported progress across several operational metrics while trading near the bottom of its 52-week range at $0.004 per share, down 92% over the past year. The presentation highlighted the company’s position across three growing healthcare segments—cancer survivorship, heart failure monitoring, and medical weight management—while management candidly acknowledged that sales performance remains "below where we would like to see them," according to the recent earnings call. As detailed in the company’s Q4 results summary, ImpediMed reported revenue of $3.6 million AUD for the quarter, with total contract value (TCV) of $5.4 million and annual recurring revenue (ARR) reaching $14.4 million as of June 30, 2026.
Read the full report at Investing.com · Company News ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
- What's the story?
- ImpediMed Limited (ASX:IPD) presented its fourth-quarter fiscal 2026 results on July 28, 2026, showing improved cash collections and unit sales but acknowledging execution challenges that have weighed on the stock. The medical device company, which sells its SOZO digital health platform for fluid and body composition monitoring, reported progress across several operational metrics while trading near the bottom of its 52-week range at $0.004 per share, down 92% over the past year.
- How widely is it covered?
- 2 outlets, average source rating 5.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
ImpediMed Q4 FY26 slides: mixed results despite improved cash position
Sources1TypeCoverageInvesting.com · Company News